When discussing ROI for devices like PatScope, it is important to distinguish between the investor's perspective and the customer's perspective (the clinic or hospital buying the equipment).

The timelines for these two groups are vastly different due to regulatory hurdles and clinical adoption rates.

1. Investor Perspective (Funding the Company)

Investors in a medical or cosmetic device startup usually expect a longer horizon due to the "MedTech Valley of Death"—the period between prototyping and receiving regulatory clearance (FDA/CE).

 

Angel Investors: Expected ROI in 5–8, years, 10x–20x return

Venture Capital (Early): Expected ROI in 7–10 years, 30%–40% IRR (Internal Rate of Return)

Private Equity (Late): Expected ROI in 3–5 years, 2x–5x return (usually for mature companies)

 

Key Factors Influencing Investor ROI:

• Regulatory Pathway: A "Class II" device (which digital dermoscopy often is) usually takes 1–3 years for clearance. A "Class III" (higher risk) can take 5+ years, pushing the ROI further back.

• Exit Strategy: ROI is often realized only through an exit (Acquisition by a giant like Hillrom or FotoFinder, or an IPO), not through dividends.

• Software vs. Hardware: Devices that include AI-driven "Software as a Service" (SaaS) for image analysis are currently more attractive to investors because they offer recurring revenue, which accelerates the ROI timeline.

​

2. Customer Perspective (The Clinic/Physician)

If you are asking what a clinic owner (the "end investor") should expect after buying a digital dermoscopy system (typically costing $4,000 to $8,000+), the timeline is much shorter.

• Payback Period: Usually 12–24 months.

• Revenue Drivers:

  • Direct Billing: In many regions, digital "mapping" of moles has specific reimbursement codes.

  • Patient Retention: Cosmetic patients are more likely to return to a clinic that provides "before and after" high-res tracking of skin health.

  • Efficiency: Digital systems speed up the workflow compared to manual handheld scopes, allowing more patients per hour.

​

3. Medical vs. Cosmetic: The "ROI Gap"

The "Cosmetic" side of the market often sees faster ROI than the "Medical" side for one primary reason: Reimbursement.

• Medical (Skin Cancer): Dependent on insurance company approvals and strict clinical evidence. ROI is steady but slower to scale.

• Cosmetic (Aesthetics): Driven by out-of-pocket payments from patients. Prices are set by the market, not insurance, allowing for higher margins and a faster return on the initial investment (often under 1 year if the clinic has high foot traffic).

​​

Summary Recommendation

PATTERNOX expected ROI is around a 5-year horizon with a focus on acquisition. Medical doctors, should expect 24-month payback period through increased patient throughput and high-value mapping services.

​